Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer

详细信息    查看全文

• 作者：John W. Smith II¹ ; ^{john.smith@usoncology.com" class="auth_mail" title="E-mail the corresponding author} ; Svetislava Vukelja² ; Anthony D. Hoffman³ ; Vicky E. Jones⁴ ; Kristi McIntyre⁵ ; Erhan Berrak⁶ ; James X. Song⁶ ; Joyce O'Shaughnessy⁷
• 关键词：Adjuvant therapy ; Chemotherapy ; ER-positive ; Halaven ; HER2-negative
• 刊名：Clinical Breast Cancer
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：16
• 期：1
• 页码：31-37
• 全文大小：416 K

文摘

The present phase II, open-label, multicenter study explored the feasibility, safety, and tolerability of eribulin, a novel non-taxane microtubule inhibitor, plus capecitabine as adjuvant therapy.

Patients and Methods

Postmenopausal women with early-stage, human epidermal growth factor receptor 2 (HER2)-negative, estrogen-receptor (ER)-positive breast cancer received four 21-day cycles of treatment with eribulin mesylate (1.4 mg/m² intravenously on days 1 and 8 of each cycle) combined with capecitabine (900 mg/m² orally twice daily on days 1-14 of each cycle [standard schedule] or 1500 mg orally twice daily using a 7-days on/7-days off schedule [weekly schedule]). Feasibility was determined by the relative dose intensity (RDI) of the combination using prespecified criteria for 80% of patients achieving an RDI of ≥ 85%, with a lower 95% confidence boundary > 70%.

Results

The mean RDI was 90.6%, and the feasibility rate was 81.3% among women (n = 67, mean age, 61.3 years) receiving the standard schedule and 95.6% and 100% among women (n = 10, mean age 62.3 years) receiving the weekly schedule. Dose reductions, missed doses, and withdrawals due to adverse events (most commonly hand-foot syndrome) ascribed to capecitabine led to a higher RDI (93.5% vs. 87.8%) and feasibility rate (82.8% vs. 71.9%) for eribulin than for capecitabine using the standard dosing schedule. The most common adverse events were alopecia and fatigue.

Conclusion

Eribulin plus capecitabine with standard or weekly dosing schedules is feasible in patients with early-stage, HER2-negative, ER-positive breast cancer. Full-dose eribulin (1.4 mg/m² on days 1 and 8) with capecitabine (1500 mg orally twice daily, 7 days on/7 days off) is recommended as a regimen for further evaluation.